Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China; Department of Anesthesiology, School of Clinical Medicine, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China.
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China; Department of Clinical Medicine, School of Clinical Medicine, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China.
Int Immunopharmacol. 2024 Apr 20;131:111846. doi: 10.1016/j.intimp.2024.111846. Epub 2024 Mar 23.
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, essential for cellular communication, orchestrates a myriad of physiological and pathological processes. Recently, the intricate association between the pathway's dysregulation and the progression of malignant tumors has garnered increasing attention. Nevertheless, there is no systematic summary detailing the anticancer effects of molecules targeting the JAK/STAT pathway in the context of tumor progression. This review offers a comprehensive overview of pharmaceutical agents targeting the JAK/STAT pathway, encompassing phytochemicals, synthetic drugs, and biomolecules. These agents can manifest their anticancer effects through various mechanisms, including inhibiting proliferation, inducing apoptosis, suppressing tumor metastasis, and angiogenesis. Notably, we emphasize the clinical challenges of drug resistance while spotlighting the potential of integrating JAK/STAT inhibitors with other therapies as a transformative approach in cancer treatment. Moreover, this review delves into the avant-garde strategy of employing nanocarriers to enhance the solubility and bioavailability of anticancer drugs, significantly amplifying their therapeutic prowess. Through this academic exploration of the multifaceted roles of the JAK/STAT pathway in the cancer milieu, we aim to sketch a visionary trajectory for future oncological interventions.
Janus 激酶/信号转导子和转录激活子（JAK/STAT）通路对于细胞通讯至关重要，它协调着无数的生理和病理过程。最近，该通路的失调与恶性肿瘤进展之间的复杂关联引起了越来越多的关注。然而，目前还没有系统的综述详细描述针对肿瘤进展中 JAK/STAT 通路的分子的抗癌作用。
本综述全面概述了靶向 JAK/STAT 通路的药物制剂，包括植物化学物质、合成药物和生物分子。这些药物可以通过多种机制发挥其抗癌作用，包括抑制增殖、诱导细胞凋亡、抑制肿瘤转移和血管生成。值得注意的是，我们强调了药物耐药性的临床挑战，同时强调了将 JAK/STAT 抑制剂与其他疗法相结合作为癌症治疗中变革性方法的潜力。此外，本综述还探讨了利用纳米载体来提高抗癌药物的溶解度和生物利用度的前沿策略，从而显著增强其治疗效果。
通过对 JAK/STAT 通路在癌症环境中的多方面作用的学术探索，我们旨在为未来的肿瘤干预勾勒出一个有远见的轨迹。
